Forecast: rough seas for leukemia

Cancer Discov. 2014 Mar;4(3):278-9. doi: 10.1158/2159-8290.CD-14-0084.

Abstract

Expression of BCL-2, BCL-XL, and MCL-1 in acute myelogenous leukemia is highly variable. Cellular BH3 profiling can help decide which are likely to respond to BCL-2-targeted BH3 mimetics.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Peptide Fragments / metabolism*
  • Proto-Oncogene Proteins / metabolism*
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Sulfonamides / pharmacology*

Substances

  • Antineoplastic Agents
  • Bax protein (53-86)
  • Bridged Bicyclo Compounds, Heterocyclic
  • Peptide Fragments
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax